Author:
Kounis Nicholas G.,Mplani Virginia
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Li MT, He Y, Huang SY, Hu X, Chen JS (2024) Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis. Invest New Drugs 42:116–126
2. Bharathidasan K, Abdelnabi M, Abdelmalek J, Sekhon J, Butler W, Quirch M, Sosa EA (2023) Nivolumab-induced fatal myocarditis: a case report. Clin Case Rep 11:e7306
3. Itzhaki Ben Zadok O, Levi A, Divakaran S, Nohria A (2023) Severe vs nonsevere immune checkpoint inhibitor-induced myocarditis: contemporary 1-year outcomes. J Am Coll Cardiol CardioOnc 5:732–744
4. Banini M, Salvestrini V, Vultaggio A, Perlato M, Mecheri V, Cerbai C, Scotti V, Matucci A, Mangoni M, Livi L, Bonomo P (2023) Desensitization protocol for Cemiplimab-related infusion reaction in cutaneous squamous cell carcinoma: a Case Report and Literature Review. Curr Oncol 30:6699–6707
5. Sobol I, Chen CL, Mahmood SS, Borczuk AC (2020) Histopathologic characterization of myocarditis associated with Immune checkpoint inhibitor therapy. Arch Pathol Lab Med 144:1392–1396